

The Global Leader in Multiplex Molecular Diagnostics

Company Overview



About Seegene	3
Our Mission	5
Our Business	7
High Multiplex MDx Products	8
All MDx Assays in One Platform	9
Doing Less for More	11
Company History	12
Global Reach with Growing Sales Network and Talents	14

We are dreaming of a world
without diseases



About Seegene

Seegene tirelessly pursues innovation and takes on new challenges to build a better future for humanity.

With the development of proprietary high multiplex real-time PCR technologies, Seegene has produced and delivered molecular diagnostics (MDx) products capable of detecting multiple targets simultaneously. Seegene's products identify and provide a wide range of clinical information integral to diagnosis and care, enabling healthcare professionals to select the best treatment in the early stages of disease.

Also, by opening a new paradigm of diagnostics in medicine/healthcare, Seegene is playing a vital role in safeguarding humanity from diseases and allowing individuals to lead a healthy life.

Seegene's High Multiplex Real-time PCR Technologies



DPO™

Technology for multiple target amplification



TOCE™

Technology for multiple target detection



MuDT™

Technology for multiple target real-time analysis

Simultaneous detection of multiple pathogens

Early diagnosis of multiple infections (co-infections by more than one causal pathogen), allowing appropriate treatment to be applied for each causal pathogen

Precise diagnosis

Confirm certainty of infection as well as measure severity based on quantitative information of infection, supporting healthcare providers in tracking/responding to patient's condition.

Timely diagnosis

Detect multiple causal pathogens in a single test, allowing appropriate treatment regimens in the early stage.

Affordable diagnosis

Cost-effective tests not only improve patient management but also relieve financial burden of healthcare system




We can accomplish our mission with Seegene technologies

Our Mission

Seegene presents a new roadmap for standardization of molecular diagnostics and brings a healthier, better future.

Based on its efforts over the years - high multiplex real-time PCR technology, extensive expertise in product development, and digitalized development system - Seegene aims to build a system that enables any patients to have access to MDx services at hospitals of any size at reasonable costs.

MDx for More Patients and Clinicians



What is molecular diagnostics (MDx)?

Molecular diagnostics (MDx) is the latest in vitro diagnostics that detects causes of disease by analyzing nucleic acids such as DNA and RNA which contain genetic information. Powered by high accuracy and rapid result delivery, this diagnostics is suitable for early diagnosis and holds a strong potential for personalized care.

With high sensitivity and accuracy, molecular diagnostics is used to detect infectious/genetic diseases, and in recent years, it has been widely used to detect MERS, H1N1, and avian influenza infections.



Early Diagnosis



High Accuracy



Rapid Result Delivery



Personalized Care



Cutting-edge Technology



Reliable and satisfying option for
both doctors and patients

Our Business

As an active and reliable development partner Seegene is expanding its reach of MDx technology not only in diagnostics of human diseases but also in diagnostics of diseases in plants, animals and in contamination/infection of livestock, agricultural products, and seafood. Seegene is venturing into new areas that include food safety testing and companion diagnostics through technology transfer contracts.

MDx assays*

Viral & Microbial infections



- Respiratory infections
- Gastrointestinal tract infections
- Tuberculosis
- Meningitis
- Sepsis
- Trofical fever
- Thalassemia
- Tick borne

Women's healthcare



- Sexually transmitted infections (STIs)
- Human papillomavirus (HPV)
- Vaginosis
- MG & Azithromycin resistance
- MG & Moxifloxacin resistance

Drug resistance



- Vancomycin-resistant *enterococci*
- Clarithromycin-resistant *H. pylori*
- Multi-drug resistant tuberculosis (MDR)
- Extensively drug resistant tuberculosis (XDR)
- Carbapenem-resistant enterobacteriaceae (CRE)
- Extended-spectrum beta-lactamases (ESBLs)
- MRSA

Oncology & SNP



- BRAF V600E
- Thrombosis
- ApoE
- Leukemia (e.g. BCR-ABL)

Oligo and RUO reagents



- For basic research in life science, medical science, and healthcare supplies (illnesses in animal and plant)
- Inspection of livestock, food hygiene, agricultural products, and seafood
- Breed inspection and confirmation of descent/bloodline

Collaborative development



- Development of products to be applied on various diagnostic instruments
- Customized multiplex MDx products

Development and licensing of new technologies



- IVD/RUO assay manufacturing technologies
- Licensing: food safety testing, companion diagnostics, etc.
- Development of digital oligo design program (*in silico* system)

* Product availability is based on timing of each country's relevant regulatory submission and approval, and not all tests are available in all countries. Not Available for Sale in the United States.

High Multiplex MDx Products

Seegene's high multiplex assays deliver comprehensive clinical information in a single test and allows accurate and rapid diagnosis


Seegene's product pipeline

Respiratory infection	APOE*
Gastrointestinal tract infection	CYP2C19*
Sexually transmitted infection	EGFR*
Bacterial vaginosis	KRAS*
Human papillomavirus	BRAF*
Mycobacterium tuberculosis	HBV Lami-R*
Non-tuberculosis mycobacteria	HBV Ente-R*
Thrombosis	Aerobic Vaginitis*
Meningitis	Dermatophyte*
Leukemia	Transplantation*
MDR-TB/XDR-TB	Bacterial DR 6 panels*
Entero-DR	MRSA*
Vaginosis Screening	MG & AziR
Vancomycin-resistant enterococci	MG & MoxiR*
Clarithromycin-resistant <i>H. pylori</i>	Tropical Fever
Lyme&Tick-borne*	Blood infection*

* in development

Product timeline

(The number of newly launched products)



Seegene's production system is certified by ISO9001 and ISO13485 and effectively supports product quality and manufacturing consistency. Seegene maintains the quality control of products and registers products in compliance to appropriate quality system requirement and country-specific regulations such as CE-IVD, Health Canada and Korean MFDS.

** Product availability is based on timing of each country's relevant regulatory submission and approval, and not all tests are available in all countries. Not Available for Sale in the United States.




Digitalized Development System

With diversified MDx built on end-to-end digitalized development processes, Seegene aims to deliver high-quality healthcare products and service.

All MDx Assays in One Platform

Seegene's All-in-One Platform is a unique streamlined automation solution and comprehensive MDx testing system that covers infectious diseases, women's health, personalized medicine and etc. The platform allows MDx to be widely used for fact-based decision making within clinically meaningful timeframe.



Less labor and space, but high productivity

- Minimal labor required by running multiple assays simultaneously on Seegene's All-in-One Platform
- Minimum hands-on time & no manual pipetting
- Compact-sized instruments requiring less lab space

Cost-effective system

- Seegene's multiplex assay can reduce the number of singleplex tests
- Various assays can be performed in one platform system with no need to purchase additional instruments.



Healthier life for all humanity

Doing Less for More

Seegene's technology leads to effective treatment.



For physicians and clinics

- Timely care in early stages of illnesses thanks to detection of multiple pathogens in a single test
- Support in selecting the best care for each casual pathogen



For technicians and clinical labs

- Increased efficiency thanks to ability to test multiple pathogens in a single test
- Early and prompt treatment for critically ill patients by preventing delays in diagnosis



For patients

- Reliable treatment based on the most accurate prescription for each causal pathogen
- Effective illness prevention and medical cost savings thanks to accurate, early diagnosis



For basic life science researchers


- Development of novel medications ideally suited to patients' needs
- Diverse applications in the development of products for diagnostic and research purposes



For governments

- Rapid diagnoses of infectious diseases newly/epidemicly spreading and reinforced national preventive measures
- Improvement of healthcare management with limited sources

Company History



2016

- Established Biodist-Seegene Diagnostics in Mexico, a joint venture with Biodist Group
- Launched SG Oligo designing system
- Awarded the 2016 South Korea In-Vitro Diagnostics Company of the Year (Frost & Sullivan)

2017

- Establish a subsidiary - Seegene Germany GmbH -in Germany
- Develop New Normalization Software Technology for molecular diagnosis

2018

- First successful development of molecular diagnosis reagents using SGDDS



2009

- Selected as official 'World class product of KOREA'
- Selected as one of the world's top 30 companies manufacturing MDx products for infections (Research and Markets)
- Approved for HT Certification by the Ministry of Health and Welfare of Korea

2011

- Developed TOCE™ technology
- Obtained KGMP certification (MFDS)

2010

- Listed on the KOSDAQ stock exchange
- Awarded the President's prize for Technology Innovation (SMBA)
- Established a branch office in Germany

2012

- Awarded the Executive of the Year as a Gold Stevie winner (The International Business Awards)

Global Reach with Growing Sales Network and Talents

Seegene has established global sales networks covering more than 60 countries around the world, and 6 overseas subsidiaries in North and South America, Europe and the Middle East that drive and support Seegene's global business operation. Seegene strives to satisfy customers in all these regions by listening and responding to their needs enthusiastically in a timely manner.

HEADQUARTERS

Seegene Inc.
Taewon Bldg. 91 Ogeum-ro, Songpa-gu, Seoul 05548, Republic of Korea
Tel +82-2-2240-4000 / FAX +82-2-2240-4040
E-mail: info@seegene.com

EUROPE

- Italy
- Austria
- Belgium
- Bulgaria
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Latvia
- Lithuania
- Macedonia
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovenia
- Slovakia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Uzbekistan

AMERICA

- USA
- Mexico
- Bolivia
- Brazil
- Canada
- Chile
- Colombia
- Costa Rica
- Ecuador
- El Salvador
- Guatemala
- Peru
- Venezuela

OCEANIA

- Australia

SUBSIDIARIES

- Seegene Germany GmbH
- Seegene TECHNOLOGIES Inc. (U.S.A)
- Seegene CANADA Inc.
- Seegene MIDDLE EAST
- Seegene MEXICO
- Seegene BRAZIL

ASIA


- Republic of Korea
- Bangladesh
- China
- Hong Kong
- India
- Indonesia
- Japan
- Pakistan
- Philippines
- Malaysia
- Mongolia
- Singapore
- Sri Lanka
- Taiwan
- Thailand
- Vietnam

MIDDLE-EAST/ AFRICA

- UAE
- Algeria
- Egypt
- Iran
- Israel
- Kenya
- Kuwait
- Lebanon
- Nigeria
- Qatar
- Saudi Arabia
- South Africa







The Global Leader in
Multiplex Molecular Diagnostics